HPV vaccine pilot shows promise for High-Risk groups
NCT ID NCT06588257
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed pilot study enrolled 101 transgender women and men who have sex with men to see how acceptable the HPV vaccine (Gardasil 9) is in these groups. Participants received three doses over six months, and researchers tracked how many completed the series and how common anal HPV infections were. The goal is to improve vaccine uptake and reduce HPV-related cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HPV vaccine (Gardasil 9)
What this could lead to
If successful, this could help improve HPV vaccination rates and reduce anal cancer risk in these groups.
What could go wrong
This is a small, completed pilot study focused on acceptability, not on proving the vaccine prevents disease. Results may not apply to broader populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fundación Huésped
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1427CEA, Argentina